SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00335166. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Study identification
- NCT ID
- NCT00335166
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 330 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2006 (Type not available)
- Primary completion
- Feb 2008 (Actual)
- Completion
- Feb 2008 (Actual)
- Last update posted
- Apr 3, 2008
2006 – 2008
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 419 | Birmingham | Alabama | — | — |
| 413 | Oceanside | California | — | — |
| 408 | Oxnard | California | — | — |
| 422 | New Haven | Connecticut | — | — |
| 403 | Boca Raton | Florida | — | — |
| 411 | Sarasota | Florida | — | — |
| 421 | Augusta | Georgia | — | — |
| 410 | Fort Wayne | Indiana | — | — |
| 417 | Lexington | Kentucky | — | — |
| 405 | Boston | Massachusetts | — | — |
| 420 | Boston | Massachusetts | — | — |
| 415 | Grand Rapids | Michigan | — | — |
| 416 | Golden Valley | Minnesota | — | — |
| 406 | Minneapolis | Minnesota | — | — |
| 418 | Albany | New York | — | — |
| 424 | Charlotte | North Carolina | — | — |
| 412 | Raleigh | North Carolina | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00335166, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2008 · Synced Nov 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.